ENO2 and stage 5 chronic kidney disease: Sharain and colleagues, in their studies comparing NSE levels in a control group with patient groups (chronic kidney disease and end-stage renal failure), showed a linear increase in NSE concentration with the progression of nephrological disorders, indicating the following trends: 3.97 for patients with chronic kidney disease and 7.46 for patients with end-stage renal failure, with a constant value of 1.00 for the control group.